BCL2L1 and osteosarcoma: Here, we provide additional evidence that Bcl-xL could be used as a relevant therapeutic target in combination with chemotherapy in osteosarcomas, with BH3-mimetic derivates for example to inhibit Bcl-xL family members and improve sensitivity to conventional chemotherapy.